Price T Rowe Associates Inc 89bio, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 42,316 shares of ETNB stock, worth $338,528. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,316
Previous 34,182
23.8%
Holding current value
$338,528
Previous $274,000
14.6%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ETNB
# of Institutions
158Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$121 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$113 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$63.9 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$59 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$56.1 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $372M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...